2012
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research 2012, 72: 3987-3996. PMID: 22869585, PMCID: PMC4384890, DOI: 10.1158/0008-5472.can-12-1337.Peer-Reviewed Original ResearchConceptsIL-12IL-23Antibody treatmentImmune systemCD40 antibody treatmentIL‐12/23p40 antibodiesAutoimmune inflammatory disorderMonoclonal antibody treatmentOccult neoplasiaOccult cancerIL-17IL-23p19IL-12/23p40Immune controlInflammatory disordersTumor immunogenicityIL-4Malignant potentialCancer immunoeditingTumor outgrowthElimination phaseTumor growthTumor dormancyMutant cancersCancer cells
2008
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 652-656. PMID: 18178624, PMCID: PMC2206591, DOI: 10.1073/pnas.0708594105.Peer-Reviewed Original ResearchConceptsCancer immunoeditingWT controlsAdaptor myeloid differentiation factor 88Myeloid differentiation factor 88Adaptive immune surveillanceMyD88-/- miceMyD88-deficient miceRole of TNFDMBA/TPAInflammation-induced cancerDistinct mouse modelsTNF-deficient miceInflammation-induced carcinogenesisO-tetradecanoylphorbol 13Mouse tumor modelsFactor 88WT miceChronic inflammationMCA sarcomaProinflammatory processesTumor immunologistsImmune surveillanceMouse modelSkin papillomasPrimary tumorigenesis